中药“808”联合拉米夫定治疗活动性肝炎肝硬变

Combined treatment of active liver cirrhosis with Chinese Traditional Medicine-808 and Lamivudine.

目的:研究中药"808"联合拉米夫定治疗活动性肝炎肝硬变的临床疗效。方法:随机选择ALC 62例,用分层随机抽样法随机平均分为治疗组和对照组。治疗组:温补肾阳、清热解毒、活血化瘀中药,1帖/3日加拉米夫定0.1/日;对照组:拉米夫定0.1g/日加退黄、保肝及对症治疗。疗程6～18 mo。结果:治疗组血清HBVDNA阴转率90.32％(28/31),和对照组相比,差异显著(P<0.01);两组治疗后,血清生化总胆红素、谷丙转氨酶、球蛋白明显下降,白蛋白明显升高,两组相比,差异显著(P<0.01);B超门静脉宽度变窄,两组相比,差异显著(P<0.05);临床存活率:治疗组为93.75％,对照组为74.19％,两组相比,差异显著(P<0.01)。结论:中药“808'’联合拉米呋啶治疗ALC,能抑制病毒复制,改善肝脏循环和肝功能,提高ALC的存活率。

Objective: To study the clinical efficacy of active liver cirrhosis (ALC) with traditional herbs medicine and Lamivudine. Methods: 62 cases of ALC wrer randomly selected and divided into treatment group and control group. Treatment group was treated with 808 (Chinese Traditional Medicine) a dose/3d and Lamivudine 0.1 g/d; Control group was treated with Lamivudine 0.1g/d.The time of treatment was 6-18 months. Result: HBVDNA in the serum changed from positive to negative, the rate of treatment group was 90.32% ( 28/31 ) , the control group 3.2% (1/31) ( P<0.01 ) . After treatment, we found the levels of total bilirubin (TB), ALT, globulin (G) in treatment group were lower and allumin (A) was higher than control group ( P<0.01 ) . The width of portal vein checked with ultrasonic B showed that in the control group is wider than that in Efficacy treatment group ( P<0.05 ) . Survival rate in treatment group was 93.75%, and in control group 74.19% ( P<0.01 ) . Conclusions: Efficacy of traditional herbs medicine with Lamivudine treating ALC shows that HBV can suppressed be the liver microcirculation can be improved, and liver function can be improved, The survival existence rate of ALC in treatment group is higher than that in control group.